In IMpower150,74 an open-label Phase 3 randomised trial of patients with metastatic non-squamous NSCLC and any level of tumour cell PD-L1 expression (including patients with EGFR or ALK genetic alterations), a combination of carboplatin, paclitaxel, bevacizumab plus atezolizumab was superior to carboplatin, paclitaxel and bevacizumab with respect to OS (overall HR 0.78, 95% CI 0.64–0.96) and PFS (overall HR 0.62, 95% CI 0.52–0.74). This evidence concerns the gene CD274 and neoplasm.